An Observational Parallel Group Phase 4 Study to Determine Progression-Free Survival and Evaluate Patient Experience for Patients With Metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC) Treated With ALK Inhibitors
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs Brigatinib (Primary) ; Alectinib; Anaplastic lymphoma kinase inhibitors; Ceritinib; Lorlatinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 29 Jul 2019 Planned number of patients changed from 400 to 160.
- 18 Jul 2019 Planned End Date changed from 14 Jun 2021 to 30 May 2022.
- 18 Jul 2019 Planned primary completion date changed from 14 Jun 2021 to 30 Apr 2022.